Brexucabtagene autoleucel shows promising efficacy and safety in treating relapsed B-cell acute lymphoblastic leukemia, including patients with CNS involvement.
Tony Berberabe, MPH
Advertisement
Articles by Tony Berberabe, MPH
Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) in the phase 3 FLAURA2 study.
Advertisement
Latest Updated Articles
Regardless of CNS Involvement, Patients With B-ALL Benefit From Brexu-CelPublished: August 23rd 2025 | Updated:
- Fine Print of Budget Deal Doesn't Bode Well for SGR Overhaul
Published: February 12th 2014 | Updated:
- Physician Practices, Healthcare Organizations See Own Staff as Source of Security Breaches
Published: March 20th 2014 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Medicaid Work Requirements Set to Leave Millions Without Insurance
2
Most Favored Nation Drug Pricing Moves Forward, but Experts Warn Details Are Still Missing
3
AMCP Nexus 2025: Advancing Health Policy and Patient Outcomes Together
4
Oncology Landscape Continues to Evolve With Expanded Indications, First-in-Class Therapies
5
